Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin
Author:
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Link
http://www.nature.com/articles/srep30091.pdf
Reference28 articles.
1. Coates, A. S. et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26, 1533–1546, 10.1093/annonc/mdv221 (2015).
2. Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A. & Caggiano, V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109, 1721–1728, 10.1002/cncr.22618 (2007).
3. Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13, 4429–4434, 10.1158/1078-0432.CCR-06-3045 (2007).
4. von Minckwitz, G. & Martin, M. Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann Oncol 23 Suppl 6, vi35–39, 10.1093/annonc/mds193 (2012).
5. Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164–172, 10.1016/S0140-6736(13)62422-8 (2014).
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Prognostic predictive value of Ki-67 in stage I–II triple-negative breast cancer;Future Science OA;2023-11-23
2. Varying outcomes of triple-negative breast cancer in different age groups–prognostic value of clinical features and proliferation;Breast Cancer Research and Treatment;2022-10-19
3. Varying outcomes of triple-negative breast cancer in different age groups - prognostic value of clinical features and proliferation;2022-08-08
4. Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer;Frontiers in Oncology;2021-11-09
5. Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer;Cancers;2021-09-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3